2001
DOI: 10.1016/s0378-4347(00)00548-x
|View full text |Cite
|
Sign up to set email alerts
|

Identification of multiple sources of charge heterogeneity in a recombinant antibody

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

27
498
3
1

Year Published

2001
2001
2022
2022

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 481 publications
(529 citation statements)
references
References 30 publications
27
498
3
1
Order By: Relevance
“…A commercial IgG1 antibody Herceptin (calculated MW ϭ 148,058 Da, Genentech, San Francisco, CA) [29]°and°a chimeric IgG2 antibody produced at Amgen (calculated MW ϭ 147,353 Da, Amgen Inc., Thousand Oaks, CA) were used in this study. The IgG2 antibody was subjected to an accelerated stability study under elevated temperatures, which caused degradations of the molecule.…”
Section: Methodsmentioning
confidence: 99%
“…A commercial IgG1 antibody Herceptin (calculated MW ϭ 148,058 Da, Genentech, San Francisco, CA) [29]°and°a chimeric IgG2 antibody produced at Amgen (calculated MW ϭ 147,353 Da, Amgen Inc., Thousand Oaks, CA) were used in this study. The IgG2 antibody was subjected to an accelerated stability study under elevated temperatures, which caused degradations of the molecule.…”
Section: Methodsmentioning
confidence: 99%
“…A label may directly perturb the function of a protein, but the reaction conditions used to introduce the label may inadvertently promote some undesirable change such as oxidation, deamidation, side-chain isomerization, or aggregation (11). The basic absence of gross changes in pharmacokinetics or molecular weight are not always sufficient characterization of labeled proteins, and binding or other functional assays may be needed to assess the integrity of an imaging probe.…”
Section: Topics Labeling: First Do No Harmmentioning
confidence: 99%
“…Therapeutic mAbs are multi-domain and multi-chain glycosylated proteins, which exhibit significant heterogeneity in structure and stability. [7][8][9][10] Specifically, the Fab and Fc regions of mAbs bear different functionality or surface properties and are expected to respond differently to various stress conditions. Therefore, these regions may contribute differently to protein stability, aggregation, and phase separation.…”
Section: Introductionmentioning
confidence: 99%